Skip to main content

Advertisement

SpringerLink
Log in

Is initial combination therapy effective in the treatment of type 2 diabetes?

  • Practice Point
  • Published:

From Nature Clinical Practice Endocrinology & Metabolism

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Riddle MC (2005) Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin North Am 34: 77–98

    Article  CAS  Google Scholar 

  2. Riddle M (2000) Combining sulfonylureas and other oral agents. Am J Med 108 (Suppl 6A): 15S–22S

    Article  CAS  Google Scholar 

  3. Zammitt NN et al. (2005) Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 28: 2948–2961

    Article  Google Scholar 

  4. UK Prospective Diabetes Study (UKPDS) Group (1995) UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44: 1249–1258

  5. Hanefeld M et al. (2004) One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 27: 141−147

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. MC Riddle is a Professor of Medicine in the Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health and Sciences University, Portland, OR, USA

    Matthew C Riddle

Authors
  1. Matthew C Riddle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew C Riddle.

Ethics declarations

Competing interests

The author has received honoraria for consulting or lectures, or research support from Amylin, Bristol-Myers Squibb, GlaxoSmithkline NovoNordisk, Lilly, Pfizer, and SanofiAventis, manufacturers of various pharmaceutical agents for diabetes.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Riddle, M. Is initial combination therapy effective in the treatment of type 2 diabetes?. Nat Rev Endocrinol 2, 254–255 (2006). https://doi.org/10.1038/ncpendmet0167

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0167

  • Springer Nature Limited

Search

Navigation